Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 12/2017

24.08.2017 | Basic Science

Topical cis-urocanic acid prevents ocular surface irritation in both IgE -independent and -mediated rat model

verfasst von: Hanna-Mari Jauhonen, Jarmo Laihia, Olli Oksala, Johanna Viiri, Reijo Sironen, Päivi Alajuuma, Kai Kaarniranta, Lasse Leino

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Our purpose was to investigate the effect of locally administered cis-urocanic (cis-UCA) in two experimental models of allergic conjunctivitis.

Methods

The compound 48/80 (C48/80)-induced ocular irritation model (IgE-independent) and the ovalbumin (OA)-induced ocular allergy model (IgE-mediated) were used to test and compare the effect of cis-UCA on dexamethasone, ketotifen and olopatadine. In the C48/80 model, clinical severity scoring from photographs, immunohistochemical analysis of nuclear Ki-67 antigen to quantify actively proliferating epithelial cells and of caspase-3 enzyme to identify apoptotic activity in the conjunctival tissue were used. In the OA model, an Evans Blue stain concentration of conjunctival tissue was used to evaluate vascular leakage due to allergic reaction.

Results

The cis-UCA was well tolerated and effective in both the IgE-independent and -mediated rat models. Treatment with C48/80 caused conjunctival hyperaemia, which was significantly inhibited by ketotifen at the 6 h time point (p = 0.014) and by dexamethasone and cis-UCA 0.5% at 12 (p = 0.004) and 24 (p = 0.004) hour time points. In a comparison between the active drug treatments, only ketotifen showed a significant difference (p = 0.023) to cis-UCA treatment at the 1 h time point, otherwise there were no statistically significant differences between the active drugs. Ketotifen, dexamethasone and cis-UCA 0.5% significantly inhibited the C48/80-induced nuclear accumulation of Ki-67, without differences between the active treatment groups. In the OA model, cis-UCA 0.5% did not inhibit the vascular leakage of conjunctiva, whereas cis-UCA 2.5% of was at least equally effective compared to olopatadine, abolishing the allergic vascular leakage response almost completely.

Conclusions

The present findings in the two AC models suggest that cis-UCA might have anti-allergic potency both in immediate and delayed-type allergic reactions in the eye.
Literatur
2.
Zurück zum Zitat Irkec MT, Bozkurt B (2012) Molecular immunology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 12:534–539CrossRefPubMed Irkec MT, Bozkurt B (2012) Molecular immunology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 12:534–539CrossRefPubMed
3.
Zurück zum Zitat Pauly A, Brasnu E, Riancho L, Brignole-Baudouin F, Baudouin C (2011) Multiple endpoint analysis of BAC-preserved and unpreserved antiallergic eye drops on a 3D-reconstituted corneal epithelial model. Mol Vis 17:745–755PubMedPubMedCentral Pauly A, Brasnu E, Riancho L, Brignole-Baudouin F, Baudouin C (2011) Multiple endpoint analysis of BAC-preserved and unpreserved antiallergic eye drops on a 3D-reconstituted corneal epithelial model. Mol Vis 17:745–755PubMedPubMedCentral
4.
Zurück zum Zitat Erdinest N, Solomon A (2014) Topical immunomodulators in the management of allergic eye diseases. Curr Opin Allergy Clin Immunol 14:457–463CrossRefPubMed Erdinest N, Solomon A (2014) Topical immunomodulators in the management of allergic eye diseases. Curr Opin Allergy Clin Immunol 14:457–463CrossRefPubMed
5.
Zurück zum Zitat Syed BA, Kumar S, Bielory L (2014) Current options and emerging therapies for anterior ocular inflammatory disease. Curr Opin Allergy Clin Immunol 14:485–489CrossRefPubMed Syed BA, Kumar S, Bielory L (2014) Current options and emerging therapies for anterior ocular inflammatory disease. Curr Opin Allergy Clin Immunol 14:485–489CrossRefPubMed
6.
Zurück zum Zitat Bjorklund S, Andersson JM, Pham QD, Nowacka A, Topgaard D, Sparr E (2014) Stratum corneum molecular mobility in the presence of natural moisturizers. Soft Matter 10:4535–4546CrossRefPubMed Bjorklund S, Andersson JM, Pham QD, Nowacka A, Topgaard D, Sparr E (2014) Stratum corneum molecular mobility in the presence of natural moisturizers. Soft Matter 10:4535–4546CrossRefPubMed
7.
Zurück zum Zitat Barresi C, Stremnitzer C, Mlitz V, Kezic S, Kammeyer A, Ghannadan M, Posa-Markaryan K, Selden C, Tschachler E, Eckhart L (2011) Increased sensitivity of histidinemic mice to UVB radiation suggests a crucial role of endogenous urocanic acid in photoprotection. J Invest Dermatol 131:188–194CrossRefPubMed Barresi C, Stremnitzer C, Mlitz V, Kezic S, Kammeyer A, Ghannadan M, Posa-Markaryan K, Selden C, Tschachler E, Eckhart L (2011) Increased sensitivity of histidinemic mice to UVB radiation suggests a crucial role of endogenous urocanic acid in photoprotection. J Invest Dermatol 131:188–194CrossRefPubMed
8.
Zurück zum Zitat Lauerma AI, Aioi A, Maibach HI (1995) Topical cis-urocanic acid suppresses both induction and elicitation of contact hypersensitivity in BALB/C mice. Acta Derm Venereol 75:272–275PubMed Lauerma AI, Aioi A, Maibach HI (1995) Topical cis-urocanic acid suppresses both induction and elicitation of contact hypersensitivity in BALB/C mice. Acta Derm Venereol 75:272–275PubMed
9.
Zurück zum Zitat Ross JA, Howie SE, Norval M, Maingay J, Simpson TJ (1986) Ultraviolet-irradiated urocanic acid suppresses delayed-type hypersensitivity to herpes simplex virus in mice. J Invest Dermatol 87:630–633CrossRefPubMed Ross JA, Howie SE, Norval M, Maingay J, Simpson TJ (1986) Ultraviolet-irradiated urocanic acid suppresses delayed-type hypersensitivity to herpes simplex virus in mice. J Invest Dermatol 87:630–633CrossRefPubMed
10.
Zurück zum Zitat Dahl MV, McEwen GN Jr, Katz HI (2010) Urocanic acid suppresses induction of immunity in human skin. Photodermatol Photoimmunol Photomed 26:303–310CrossRefPubMed Dahl MV, McEwen GN Jr, Katz HI (2010) Urocanic acid suppresses induction of immunity in human skin. Photodermatol Photoimmunol Photomed 26:303–310CrossRefPubMed
11.
Zurück zum Zitat Rinaldi M, Moroni P, Leino L, Laihia J, Paape MJ, Bannerman DD (2006) Effect of cis-urocanic acid on bovine neutrophil generation of reactive oxygen species. J Dairy Sci 89:4188–4201CrossRefPubMed Rinaldi M, Moroni P, Leino L, Laihia J, Paape MJ, Bannerman DD (2006) Effect of cis-urocanic acid on bovine neutrophil generation of reactive oxygen species. J Dairy Sci 89:4188–4201CrossRefPubMed
12.
Zurück zum Zitat Bannerman DD, Rinaldi M, Vinyard BT, Laihia J, Leino L (2009) Effects of intramammary infusion of cis-urocanic acid on mastitis-associated inflammation and tissue injury in dairy cows. Am J Vet Res 70:373–382CrossRefPubMed Bannerman DD, Rinaldi M, Vinyard BT, Laihia J, Leino L (2009) Effects of intramammary infusion of cis-urocanic acid on mastitis-associated inflammation and tissue injury in dairy cows. Am J Vet Res 70:373–382CrossRefPubMed
13.
Zurück zum Zitat Peltonen JM, Pylkkanen L, Jansen CT, Volanen I, Lehtinen T, Laihia JK, Leino L (2014) Three randomised phase I/IIa trials of 5% Cis-urocanic acid emulsion cream in healthy adult subjects and in patients with atopic dermatitis. Acta Derm Venereol 94:415–420CrossRefPubMed Peltonen JM, Pylkkanen L, Jansen CT, Volanen I, Lehtinen T, Laihia JK, Leino L (2014) Three randomised phase I/IIa trials of 5% Cis-urocanic acid emulsion cream in healthy adult subjects and in patients with atopic dermatitis. Acta Derm Venereol 94:415–420CrossRefPubMed
14.
Zurück zum Zitat Viiri J, Jauhonen HM, Kauppinen A, Ryhanen T, Paimela T, Hyttinen J, Sorri I, Laihia JK, Leino L, Kaarniranta K (2009) Cis-urocanic acid suppresses UV-B-induced interleukin-6 and -8 secretion and cytotoxicity in human corneal and conjunctival epithelial cells in vitro. Mol Vis 15:1799–1805PubMedPubMedCentral Viiri J, Jauhonen HM, Kauppinen A, Ryhanen T, Paimela T, Hyttinen J, Sorri I, Laihia JK, Leino L, Kaarniranta K (2009) Cis-urocanic acid suppresses UV-B-induced interleukin-6 and -8 secretion and cytotoxicity in human corneal and conjunctival epithelial cells in vitro. Mol Vis 15:1799–1805PubMedPubMedCentral
15.
Zurück zum Zitat Jauhonen HM, Kauppinen A, Paimela T, Laihia JK, Leino L, Salminen A, Kaarniranta K (2011) Cis-urocanic acid inhibits SAPK/JNK signaling pathway in UV-B exposed human corneal epithelial cells in vitro. Mol Vis 17:2311–2317PubMedPubMedCentral Jauhonen HM, Kauppinen A, Paimela T, Laihia JK, Leino L, Salminen A, Kaarniranta K (2011) Cis-urocanic acid inhibits SAPK/JNK signaling pathway in UV-B exposed human corneal epithelial cells in vitro. Mol Vis 17:2311–2317PubMedPubMedCentral
16.
Zurück zum Zitat Pflugfelder SC, de Paiva CS, Tong L, Luo L, Stern ME, Li DQ (2005) Stress-activated protein kinase signaling pathways in dry eye and ocular surface disease. Ocul Surf 3:154–157CrossRef Pflugfelder SC, de Paiva CS, Tong L, Luo L, Stern ME, Li DQ (2005) Stress-activated protein kinase signaling pathways in dry eye and ocular surface disease. Ocul Surf 3:154–157CrossRef
17.
Zurück zum Zitat Tiligada E, Aslanis D, Delitheos A, Varonos D (2000) Changes in histamine content following pharmacologically-induced mast cell degranulation in the rat conjunctiva. Pharmacol Res 41:667–670CrossRefPubMed Tiligada E, Aslanis D, Delitheos A, Varonos D (2000) Changes in histamine content following pharmacologically-induced mast cell degranulation in the rat conjunctiva. Pharmacol Res 41:667–670CrossRefPubMed
18.
Zurück zum Zitat Calonge M, Siemasko KF, Stern ME (2003) Animal models of ocular allergy and their clinical correlations. Curr Allergy Asthma Rep 3:345–351CrossRefPubMed Calonge M, Siemasko KF, Stern ME (2003) Animal models of ocular allergy and their clinical correlations. Curr Allergy Asthma Rep 3:345–351CrossRefPubMed
19.
Zurück zum Zitat Sheldon WH, Bauer H (1960) Tissue mast cells and acute inflammation in experimental Cutaneous Mucormycosis of normal, 48/80-treated, and diabetic rats. J Exp Med 112:1069–1084CrossRefPubMedPubMedCentral Sheldon WH, Bauer H (1960) Tissue mast cells and acute inflammation in experimental Cutaneous Mucormycosis of normal, 48/80-treated, and diabetic rats. J Exp Med 112:1069–1084CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Dartt DA, Masli S (2014) Conjunctival epithelial and goblet cell function in chronic inflammation and ocular allergic inflammation. Curr Opin Allergy Clin Immunol 14:464–470CrossRefPubMedPubMedCentral Dartt DA, Masli S (2014) Conjunctival epithelial and goblet cell function in chronic inflammation and ocular allergic inflammation. Curr Opin Allergy Clin Immunol 14:464–470CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Allansmith MR, Baird RS, Ross RN, Barney NP, Bloch KJ (1989) Ocular anaphylaxis induced in the rat by topical application of compound 48/80. Dose response and time course study. Acta Ophthalmol Suppl 192:145–153PubMed Allansmith MR, Baird RS, Ross RN, Barney NP, Bloch KJ (1989) Ocular anaphylaxis induced in the rat by topical application of compound 48/80. Dose response and time course study. Acta Ophthalmol Suppl 192:145–153PubMed
22.
Zurück zum Zitat Groneberg DA, Bielory L, Fischer A, Bonini S, Wahn U (2003) Animal models of allergic and inflammatory conjunctivitis. Allergy 58:1101–1113CrossRefPubMed Groneberg DA, Bielory L, Fischer A, Bonini S, Wahn U (2003) Animal models of allergic and inflammatory conjunctivitis. Allergy 58:1101–1113CrossRefPubMed
23.
Zurück zum Zitat Khosravi E, Elena PP, Hariton C (1995) Allergic conjunctivitis and uveitis models: reappraisal with some marketed drugs. Inflamm Res 44:47–54CrossRefPubMed Khosravi E, Elena PP, Hariton C (1995) Allergic conjunctivitis and uveitis models: reappraisal with some marketed drugs. Inflamm Res 44:47–54CrossRefPubMed
24.
Zurück zum Zitat Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322CrossRefPubMed Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322CrossRefPubMed
25.
Zurück zum Zitat Ohara M, Sotozono C, Tsuchihashi Y, Kinoshita S (2004) Ki-67 labeling index as a marker of malignancy in ocular surface neoplasms. Jpn J Ophthalmol 48:524–529CrossRefPubMed Ohara M, Sotozono C, Tsuchihashi Y, Kinoshita S (2004) Ki-67 labeling index as a marker of malignancy in ocular surface neoplasms. Jpn J Ophthalmol 48:524–529CrossRefPubMed
26.
Zurück zum Zitat Abu El-Asrar AM, Al-Mansouri S, Tabbara KF, Missotten L, Geboes K (2006) Immunopathogenesis of conjunctival remodelling in vernal keratoconjunctivitis. Eye (Lond) 20:71–79CrossRef Abu El-Asrar AM, Al-Mansouri S, Tabbara KF, Missotten L, Geboes K (2006) Immunopathogenesis of conjunctival remodelling in vernal keratoconjunctivitis. Eye (Lond) 20:71–79CrossRef
27.
Zurück zum Zitat Calonge MC, Pastor JC, Herreras JM, Gonzalez JL (1990) Pharmacologic modulation of vascular permeability in ocular allergy in the rat. Invest Ophthalmol Vis Sci 31:176–180PubMed Calonge MC, Pastor JC, Herreras JM, Gonzalez JL (1990) Pharmacologic modulation of vascular permeability in ocular allergy in the rat. Invest Ophthalmol Vis Sci 31:176–180PubMed
28.
Zurück zum Zitat Calonge M, Montero JA, Herreras JM, Ramon JJ, Pastor JC (1996) Efficacy of nedocromil sodium and cromolyn sodium in an experimental model of ocular allergy. Ann Allergy Asthma Immunol 77:124–130CrossRefPubMed Calonge M, Montero JA, Herreras JM, Ramon JJ, Pastor JC (1996) Efficacy of nedocromil sodium and cromolyn sodium in an experimental model of ocular allergy. Ann Allergy Asthma Immunol 77:124–130CrossRefPubMed
29.
Zurück zum Zitat Sanchis-Merino ME, Montero JA, Ruiz-Moreno JM, Rodriguez AE, Pastor S (2008) Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis. Exp Eye Res 86:791–797CrossRefPubMed Sanchis-Merino ME, Montero JA, Ruiz-Moreno JM, Rodriguez AE, Pastor S (2008) Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis. Exp Eye Res 86:791–797CrossRefPubMed
30.
31.
Zurück zum Zitat Jauhonen HM, Kari E, Pylkkanen L, Poutanen J, Laihia J, Kaarniranta K, Leino L (2015) A randomized phase I clinical study of cis-urocanic acid eye drops in healthy adult subjects. Acta Ophthalmol 93:368–376CrossRefPubMed Jauhonen HM, Kari E, Pylkkanen L, Poutanen J, Laihia J, Kaarniranta K, Leino L (2015) A randomized phase I clinical study of cis-urocanic acid eye drops in healthy adult subjects. Acta Ophthalmol 93:368–376CrossRefPubMed
Metadaten
Titel
Topical cis-urocanic acid prevents ocular surface irritation in both IgE -independent and -mediated rat model
verfasst von
Hanna-Mari Jauhonen
Jarmo Laihia
Olli Oksala
Johanna Viiri
Reijo Sironen
Päivi Alajuuma
Kai Kaarniranta
Lasse Leino
Publikationsdatum
24.08.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 12/2017
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-017-3781-z

Weitere Artikel der Ausgabe 12/2017

Graefe's Archive for Clinical and Experimental Ophthalmology 12/2017 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.